PRESTIGE CONSUMER HEALTHCARE INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PRESTIGE CONSUMER HEALTHCARE INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $378.00K, a 84.65% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $752.00K, a 53.49% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $3.15M, a 59.75% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. stock issued during period, value, stock options exercised for fiscal 2026 was $4.29M, a 71.05% decline from fiscal 2025.
- PRESTIGE CONSUMER HEALTHCARE INC. stock issued during period, value, stock options exercised for fiscal 2025 was $14.80M, a 18.17% decline from fiscal 2024.
- PRESTIGE CONSUMER HEALTHCARE INC. stock issued during period, value, stock options exercised for fiscal 2024 was $18.09M, a 145.37% increase from fiscal 2023.
- PRESTIGE CONSUMER HEALTHCARE INC. stock issued during period, value, stock options exercised for fiscal 2023 was $7.37M, a 4.72% increase from fiscal 2022.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-14 | $4.29M 10-K · filed 2026-05-14 |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-05 | $6.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $752.00K 10-Q · filed 2025-11-06 | $15.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.15M 10-Q · filed 2026-08-06 | $15.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-14 | $14.80M 10-K · filed 2026-05-14 |
| 2024-12-31 | $8.75M 10-Q · filed 2026-02-05 | $19.61M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-09-30 | $1.62M 10-Q · filed 2025-11-06 | $12.50M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-06-30 | $1.98M 10-Q · filed 2025-08-07 | $13.04M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-03-31 | $7.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-14 | $18.09M 10-K · filed 2026-05-14 |
| 2023-12-31 | $1.64M 10-Q · filed 2025-02-06 | $11.02M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-09-30 | $2.15M 10-Q · filed 2024-11-07 | $15.07M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-06-30 | $7.03M 10-Q · filed 2024-08-08 | $12.91M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-03-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-09 | $7.37M 10-K · filed 2025-05-09 |
| 2022-12-31 | $5.68M 10-Q · filed 2024-02-08 | $8.49M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-02 | $5.82M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-06-30 | $1.49M 10-Q · filed 2023-08-03 | $6.33M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-03-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-15 | $7.04M 10-K · filed 2024-05-15 |
| 2021-12-31 | $3.01M 10-Q · filed 2023-02-02 | $7.25M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-09-30 | $503.00K 10-Q · filed 2022-11-03 | $4.27M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-06-30 | $2.20M 10-Q · filed 2022-08-04 | $3.84M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-03-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-05 | $2.85M 10-K · filed 2023-05-05 |
| 2020-12-31 | $39.00K 10-Q · filed 2022-02-03 | $1.64M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-09-30 | $69.00K 10-Q · filed 2021-11-04 | $2.06M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-06-30 | $1.22M 10-Q · filed 2021-08-05 | $2.27M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-03-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-06 | $1.32M 10-K · filed 2022-05-06 |
| 2019-12-31 | $463.00K 10-Q · filed 2021-02-04 | $1.01M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-09-30 | $269.00K 10-Q · filed 2020-11-05 | $2.45M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-06-30 | $275.00K 10-Q · filed 2020-08-06 | $2.33M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-07 | $2.93M 10-K · filed 2021-05-07 |
| 2018-12-31 | $1.90M 10-Q · filed 2020-02-06 | |
| 2018-09-30 | $148.00K 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $880.00K 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $1.62M 10-K · filed 2020-05-08 | |
| 2017-03-31 | $4.03M 10-K · filed 2019-05-13 | |
| 2016-03-31 | $6.69M 10-K · filed 2018-05-10 | |
| 2015-03-31 | $3.95M 10-K · filed 2017-05-17 | |
| 2014-03-31 | $5.91M 10-K · filed 2016-05-17 | |
| 2013-03-31 | $6.03M 10-K · filed 2015-05-14 | |
| 2012-03-31 | $889.00K 10-K · filed 2014-05-19 | |
| 2011-03-31 | $331.00K 10-K · filed 2013-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |